Home › Companies › Corvus Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Corvus Pharmaceuticals, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of June 11, 2026: 4 items on Corvus Pharmaceuticals, Inc.’s Form 8-K, filed June 12, 2026: 2 approved · 2 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Corvus Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Corvus Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Richard A. Miller, M.D. | 58,275,179 | -- | -- | 2,697,052 | 12,049,623 | 96% | Not verified | — |
| Elect Director: Linda S. Grais, M.D., J.D. | 53,185,380 | -- | -- | 7,786,851 | 12,049,623 | 87% | Not verified | — |
| 2. Ratification of Selection of Independent Registered Accounting Firm | 72,864,335 | 105,674 | 51,845 | -- | -- | 99.8% | Approved | — |
| Proposal 3: Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers On a non-binding advisory basis, the Company's stockholders approved the compensation of the Company's named executive officers. | 58,936,532 | 1,971,370 | 64,329 | -- | 12,049,623 | 97% | Approved | — |
Source: Corvus Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.
Each item below shows how the 174 asset managers that disclosed a Corvus Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: To elect two Class I Directors with terms to expire at the 2029 annual meeting of stockholders: Linda S. Grais, M.D. J.D.
Corvus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Linda S. Grais, M.D., J.D.”): 53,185,380 for, 7,786,851 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 59 asset managers below reported 9,619,543 for, 2,541,419 withheld, 22 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,874,948 | 0 | 22 | 0 | For |
| T. Rowe Price | 1,700,288 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 1,161,450 | Withhold |
| Fidelity | 1,021,353 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 806,415 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 550,000 | 0 | 0 | 0 | For |
| State Street | 1,336 | 0 | 0 | 410,292 | Withhold |
| Hartford | 299,985 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 0 | 288,612 | Withhold |
| Charles Schwab | 188,094 | 0 | 0 | 0 | For |
| Principal | 4,299 | 0 | 0 | 170,641 | Withhold |
| Equitable | 12,357 | 0 | 0 | 144,538 | Mixed |
| TIAA | 0 | 0 | 0 | 142,018 | Withhold |
| Victory Capital | 129,967 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,984 | 0 | 0 | 0 | For |
| Tema ETF Trust | 109,881 | 0 | 0 | 0 | For |
| Brighthouse | 89,445 | 0 | 0 | 5,395 | Mixed |
| John Hancock | 93,527 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 79,056 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 77,046 | Withhold |
| Voya | 73,427 | 0 | 0 | 0 | For |
| ProShares | 62,063 | 0 | 0 | 0 | For |
| Lincoln Financial | 9,404 | 0 | 0 | 39,400 | Mixed |
| JPMorgan | 42,768 | 0 | 0 | 0 | For |
| Transamerica | 40,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect two Class I Directors with terms to expire at the 2029 annual meeting of stockholders: Richard A. Miller, M.D.
Corvus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Richard A. Miller, M.D.”): 58,275,179 for, 2,697,052 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 59 asset managers below reported 11,646,448 for, 514,528 withheld, 8 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,865,150 | 0 | 8 | 9,813 | For |
| T. Rowe Price | 1,700,288 | 0 | 0 | 0 | For |
| BlackRock | 1,161,450 | 0 | 0 | 0 | For |
| Fidelity | 1,021,353 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 806,415 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 550,000 | 0 | 0 | 0 | For |
| State Street | 411,082 | 0 | 0 | 546 | For |
| Hartford | 299,985 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 0 | 288,612 | Withhold |
| Charles Schwab | 188,094 | 0 | 0 | 0 | For |
| Principal | 4,299 | 0 | 0 | 170,641 | Withhold |
| Equitable | 156,895 | 0 | 0 | 0 | For |
| TIAA | 142,018 | 0 | 0 | 0 | For |
| Victory Capital | 129,967 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,984 | 0 | 0 | 0 | For |
| Tema ETF Trust | 109,881 | 0 | 0 | 0 | For |
| Brighthouse | 89,445 | 0 | 0 | 5,395 | Mixed |
| John Hancock | 93,527 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 79,056 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 77,046 | 0 | 0 | 0 | For |
| Voya | 73,427 | 0 | 0 | 0 | For |
| ProShares | 62,063 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,804 | 0 | 0 | 0 | For |
| JPMorgan | 42,768 | 0 | 0 | 0 | For |
| Transamerica | 40,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Combines 5 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers.
Corvus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers On a non-binding advisory basis, the Company's stockholders approved the compensation of the Company's named exe”): 58,936,532 for, 1,971,370 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers On a non-binding advisory basis, the Company's stockholders approved the compensation of the Company's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,874,964 | 6 | 0 | 0 | For |
| T. Rowe Price | 1,700,288 | 0 | 0 | 0 | For |
| BlackRock | 1,161,450 | 0 | 0 | 0 | For |
| Fidelity | 1,021,353 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 806,415 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 550,000 | 0 | 0 | 0 | For |
| State Street | 411,453 | 175 | 0 | 0 | For |
| Hartford | 299,985 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 288,612 | 0 | 0 | 0 | For |
| Charles Schwab | 188,094 | 0 | 0 | 0 | For |
| Principal | 174,940 | 0 | 0 | 0 | For |
| Equitable | 156,895 | 0 | 0 | 0 | For |
| TIAA | 142,018 | 0 | 0 | 0 | For |
| Victory Capital | 129,967 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,984 | 0 | 0 | 0 | For |
| Tema ETF Trust | 109,881 | 0 | 0 | 0 | For |
| Brighthouse | 89,445 | 0 | 5,395 | 0 | Mixed |
| John Hancock | 93,527 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 79,056 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 77,046 | 0 | 0 | 0 | For |
| Voya | 73,427 | 0 | 0 | 0 | For |
| ProShares | 62,063 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,804 | 0 | 0 | 0 | For |
| JPMorgan | 42,768 | 0 | 0 | 0 | For |
| Transamerica | 40,700 | 0 | 0 | 0 | For |
Fund voting reports, all 59 managers: 12,096,054 for, 59,534 against, 5,395 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 7,165,006 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 2,805,816 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,609,234 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 2,487,775 | 0 | 0 | 0 | For |
| BlackRock | 2,309,937 | 12,742 | 0 | 0 | For |
| Commodore Capital LP | 2,258,735 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 2,094,764 | 0 | 0 | 0 | For |
| Foresite Capital Management VI LLC | 1,831,233 | 0 | 0 | 0 | For |
| Wellington | 1,617,761 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 1,589,593 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,269,389 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 1,263,045 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 1,255,921 | 0 | 0 | 0 | For |
| State Street | 940,980 | 2,384 | 0 | 0 | For |
| Catalio Capital Management, LP | 869,748 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 575,092 | 0 | 0 | 0 | For |
| Vanguard | 553,499 | 0 | 0 | 0 | For |
| Blue Owl Capital Holdings LP | 510,000 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 428,885 | 0 | 0 | 0 | For |
| EMERALD ADVISERS, LLC | 270,350 | 0 | 0 | 0 | For |
| Northern Trust | 256,211 | 2,028 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 217,511 | 0 | 0 | 0 | For |
| Charles Schwab | 188,129 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 180,637 | 0 | 0 | 0 | For |
| Boxer Capital Management, LLC | 176,670 | 0 | 0 | 0 | For |
Institutional-manager reports, all 129 managers: 37,491,341 for, 219,423 against, 195 abstained. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.
Corvus Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Selection of Independent Registered Accounting Firm”): 72,864,335 for, 105,674 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 59 asset managers below reported 12,155,572 for, 16 against, 5,395 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,874,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,700,288 | 0 | 0 | 0 | For |
| BlackRock | 1,161,450 | 0 | 0 | 0 | For |
| Fidelity | 1,021,353 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 806,415 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 550,000 | 0 | 0 | 0 | For |
| State Street | 411,612 | 16 | 0 | 0 | For |
| Hartford | 299,985 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 288,612 | 0 | 0 | 0 | For |
| Charles Schwab | 188,094 | 0 | 0 | 0 | For |
| Principal | 174,940 | 0 | 0 | 0 | For |
| Equitable | 156,895 | 0 | 0 | 0 | For |
| TIAA | 142,018 | 0 | 0 | 0 | For |
| Victory Capital | 129,967 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,984 | 0 | 0 | 0 | For |
| Tema ETF Trust | 109,881 | 0 | 0 | 0 | For |
| Brighthouse | 89,445 | 0 | 5,395 | 0 | Mixed |
| John Hancock | 93,527 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 79,056 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 77,046 | 0 | 0 | 0 | For |
| Voya | 73,427 | 0 | 0 | 0 | For |
| ProShares | 62,063 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,804 | 0 | 0 | 0 | For |
| JPMorgan | 42,768 | 0 | 0 | 0 | For |
| Transamerica | 40,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 84,090,424 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.61% |
| 2 | T. Rowe Price | 2.02% |
| 3 | BlackRock | 1.38% |
| 4 | Fidelity | 1.21% |
| 5 | Manager Directed Portfolios | 0.96% |
| 6 | MUTUAL FUND SERIES TRUST | 0.65% |
| 7 | State Street | 0.49% |
| 8 | Hartford | 0.36% |
| 9 | RBB FUND, INC. | 0.34% |
| 10 | Charles Schwab | 0.22% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 8.52% |
| 2 | Vivo Capital, LLC | 3.34% |
| 3 | T. Rowe Price | 3.10% |
| 4 | Deep Track Capital, LP | 2.96% |
| 5 | BlackRock | 2.76% |
| 6 | Commodore Capital LP | 2.69% |
| 7 | Polar Capital Holdings Plc | 2.49% |
| 8 | Foresite Capital Management VI LLC | 2.18% |
| 9 | Wellington | 1.92% |
| 10 | MPM BioImpact LLC | 1.89% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| OrbiMed Private Investments V, LP | 8.52% | DEF14A |
| Peter A. Thompson, M.D. | 8.52% | DEF14A |
| Entities affiliated with Sirenia Capital Management LP | 8.12% | DEF14A |
| BlackRock | 7.33% | 13F |
| Richard A. Miller | 7.24% | 13G |
| Vanguard Group | 4.61% | 13F |
| Morgan Stanley | 4.24% | 13F |
| State Street | 4.24% | 13F |
| Adams Street Partners, LLC | 3.90% | 13D |
| T. Rowe Price | 3.47% | 13F |
Percentages above are of 84,090,424 shares outstanding, as reported by Corvus Pharmaceuticals, Inc. on its Form 10-Q dated May 7, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Corvus Pharmaceuticals, Inc.’s 10-Q dated May 7, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At Corvus Pharmaceuticals, Inc.'s shareholder meeting held June 11, 2026, in the 2025-2026 proxy season, 174 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 893 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers. — Corvus Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Corvus Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.
Corvus Pharmaceuticals, Inc. proxy season coverage: 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.